Abstract
Fine structural changes in the hepatic microbodies of male adult rats treated with a newly developed hypolipidemic agent, gemfibrozil, were compared with results of clofibrate treatment. Both drugs caused a hepatic microbody proliferation and elevation of the catalase activity in the liver, in spite of their different chemical structures. A significant difference was observed, however, in the ultrastructure of the microbodies of the two drugs. An appearance of tubular substructure was evident in the matrix of hepatic microbodies due to the effect of gemfibrozil, in contrast to clofibrate which caused an occurrence of fibrous substructures.
